Last updated: July 31, 2026
Bryhali is a branded topical psoriasis drug with a differentiated lotion vehicle, a narrow approved indication, and limited standalone disclosure. Its investment case depends on prescription retention, payer access, dermatology sales execution, and the durability of formulation and method-of-use protection. The product has lower clinical and manufacturing risk than a novel systemic drug, but its addressable market and revenue visibility are also materially smaller.
What is Bryhali and who markets it?
Bryhali is the brand name for halobetasol propionate lotion, 0.01%, a topical corticosteroid approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in patients 18 years and older.[1]
| Item |
Bryhali |
| Active ingredient |
Halobetasol propionate |
| Strength |
0.01% |
| Dosage form |
Topical lotion |
| Drug class |
Very-high-potency topical corticosteroid |
| Approved indication |
Plaque psoriasis in adults |
| Maximum labeled treatment duration |
Up to eight weeks |
| Initial FDA approval |
2018 |
| Commercial organization |
Ortho Dermatologics, part of Bausch Health |
| Primary market |
United States |
| Delivery route |
Topical |
| Biosimilar exposure |
None |
Bryhali is positioned against established topical corticosteroids, including generic halobetasol ointment, cream and foam products, as well as branded nonsteroidal therapies such as Enstilar, Zoryve and Vtama.
The commercial distinction is the lotion formulation. The product is designed for use on plaque psoriasis, including areas where an ointment may be less acceptable to patients. Bryhali's label permits once-daily application for up to eight weeks, followed by discontinuation when control is achieved.[1]
What clinical and regulatory milestones support Bryhali?
The FDA approved Bryhali on the basis of two randomized, double-blind, vehicle-controlled Phase 3 studies in adults with moderate-to-severe plaque psoriasis.[1] The primary endpoint was treatment success at week eight, defined by a specified Investigator's Global Assessment response and improvement from baseline.
The label reported materially higher treatment success for Bryhali than for vehicle in both pivotal studies. The safety profile was consistent with other potent topical corticosteroids. Reported risks include local reactions, hypothalamic-pituitary-adrenal axis suppression, skin atrophy and other corticosteroid-related effects, particularly with prolonged use or application over large areas.[1]
FDA regulatory status
Bryhali is an FDA-approved prescription drug. It is not a biologic and does not require a biosimilar pathway. Generic competition would proceed through an Abbreviated New Drug Application, subject to the applicable Orange Book patent certifications and regulatory requirements.
The product does not have the development profile of a new molecular entity. Its investment value is tied to formulation, brand, distribution and commercial execution rather than discovery-stage clinical innovation.
What patents protect Bryhali?
Bryhali's relevant intellectual-property protection is expected to center on the lotion formulation, the composition of the product, and methods of treating plaque psoriasis with halobetasol propionate lotion.
Public FDA and patent records identify patent protection associated with halobetasol propionate topical compositions and Bryhali's lotion formulation. The Orange Book is the controlling source for patents listed against the approved product and must be read together with the relevant patent documents and FDA listing data.[2]
| Protection category |
Investment relevance |
| Composition and formulation patents |
Can delay or complicate generic substitution |
| Method-of-use patents |
May cover treatment of plaque psoriasis or specified dosing |
| Drug-product listing |
Determines the scope of Orange Book certification exposure |
| Manufacturing know-how |
May create practical barriers not visible in the Orange Book |
| Trademark and trade dress |
Supports brand retention but does not prevent generic approval |
A key distinction is the difference between a patent's nominal expiration date and its effective commercial value. A formulation patent may be commercially useful if it covers the specific lotion architecture required for an ANDA product. A method-of-use patent has less blocking value if a generic applicant can use a section viii statement and omit the patented indication from its label.
How strong is the Bryhali patent estate?
The estate appears more defensible than a simple active-ingredient patent position because halobetasol propionate is an old corticosteroid with extensive generic competition. Protection must therefore come from the product's vehicle, concentration, delivery characteristics, or approved use.
The principal strengths are:
- A branded lotion dosage form distinct from older halobetasol ointment and cream products.
- Potential formulation claims that may require a generic applicant to design around the vehicle.
- A prescription product with an established FDA safety and efficacy record.
- Commercial differentiation based on tolerability, cosmetic acceptability and patient adherence.
The principal weaknesses are:
- Halobetasol propionate is a mature active ingredient.
- Generic manufacturers can challenge listed patents through Paragraph IV certifications.
- Topical products may be vulnerable to formulation design-arounds.
- A generic may obtain approval while carving out a patented indication.
- Patent protection does not guarantee formulary access or prescription growth.
When does Bryhali lose exclusivity?
Bryhali's regulatory exclusivity was limited compared with a new chemical entity because the product uses an established active ingredient. The principal long-term barrier is patent protection, not orphan-drug or NCE exclusivity.
| Exclusivity factor |
Effect on Bryhali |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No material standalone protection identified in the core approval profile |
| Orange Book patents |
Potentially the principal generic-entry barrier |
| Brand and formulation differentiation |
Commercial protection after regulatory exclusivity |
| Generic substitution |
Depends on ANDA approval and state substitution rules |
The practical generic-entry date depends on the latest enforceable Orange Book patent, any Paragraph IV litigation, settlement terms, pediatric extensions, regulatory review timing and the commercial feasibility of a competing topical formulation.
Because Bryhali uses an old active ingredient, investors should not value the asset using the exclusivity assumptions applied to a novel oral or injectable drug. The relevant question is how long the formulation can retain a premium over generic halobetasol.
What is the Orange Book status of Bryhali?
Bryhali is an FDA-approved prescription drug that may have listed patents in the FDA Orange Book. Orange Book listings determine whether an ANDA applicant must submit a Paragraph IV certification or may use another certification pathway.[2]
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. The filing can trigger patent litigation and a statutory 30-month stay of FDA approval if the patent owner or exclusive licensee files suit within the applicable period.[3]
For Bryhali, the most important Orange Book questions are:
- Which formulation patents are currently listed?
- What claims do those patents cover?
- Which listed patents expire first?
- Do the claims cover the active product or only a particular vehicle?
- Can a generic applicant use a section viii statement to omit a patented use?
- Has any ANDA applicant filed a Paragraph IV challenge?
- Has Bausch Health disclosed a settlement or authorized-generic arrangement?
Which companies are challenging Bryhali?
No major publicly disclosed Bryhali Paragraph IV challenge should be treated as established without a current FDA or court-record confirmation. Generic topical manufacturers with relevant capabilities include Taro Pharmaceutical Industries, Perrigo, Padagis, Glenmark, Actavis, Teva and Amneal, although capability does not establish that any company has filed an ANDA or challenged a Bryhali patent.
The most credible challengers would have:
- Existing halobetasol products or topical corticosteroid manufacturing capacity.
- Experience with semisolid formulation equivalence.
- Access to dermatology distribution channels.
- Sufficient regulatory resources to address topical bioequivalence requirements.
- A commercial rationale for entering a relatively concentrated branded niche.
Topical ANDA development can be more complex than oral-solid-dose development because the applicant may need to demonstrate pharmaceutical equivalence, product quality and local or comparative performance. That complexity can delay entry, but it does not eliminate the threat.
What generic entry risks exist for Bryhali?
Bryhali faces three principal generic scenarios.
Scenario 1: Delayed generic entry
A generic applicant challenges a listed patent, litigation proceeds, and market entry is delayed until patent expiry, settlement date or an adverse court outcome. This scenario preserves the longest period of branded pricing but may still involve pre-launch payer pressure.
Scenario 2: Authorized generic or licensed entry
Bausch Health permits a generic partner to enter before full patent expiry. This can monetize the product after branded demand begins to decline, but it normally reduces branded net sales and price realization.
Scenario 3: Formulation design-around
A competitor develops a lotion or topical product that avoids asserted claims while achieving comparable performance. This creates the highest risk because it can bypass the strongest product-specific patent without waiting for all patent terms to expire.
The commercial impact would likely be gradual rather than instantaneous if competing topical products require formulary contracting, dermatology promotion and pharmacy adoption. Automatic substitution risk depends on the generic's FDA-rated equivalence and the state in which dispensing occurs.
How does Bryhali compare with competing psoriasis drugs?
| Product |
Active ingredient |
Type |
Competitive position |
| Bryhali |
Halobetasol propionate |
Very-high-potency topical corticosteroid lotion |
Differentiated vehicle and established steroid efficacy |
| Generic halobetasol |
Halobetasol propionate |
Cream, ointment, foam or other topical forms |
Low-cost substitute |
| Lexette |
Halobetasol propionate |
Foam |
Competes on vehicle and usability |
| Enstilar |
Calcipotriene/betamethasone |
Foam |
Non-identical combination therapy |
| Vtama |
Tapinarof |
Nonsteroidal cream |
Steroid-sparing branded competitor |
| Zoryve |
Roflumilast |
Nonsteroidal cream or foam |
Chronic-use and steroid-free positioning |
| Taclonimus or pimecrolimus products |
Calcineurin inhibitors |
Nonsteroidal topical therapies |
More relevant in selected sensitive areas |
| Systemic biologics |
Multiple mechanisms |
Injectable or oral |
Used for broader or more severe disease |
Bryhali's advantages are familiarity, potency, once-daily dosing and a lotion vehicle. Its limitations are the short labeled treatment duration, corticosteroid safety restrictions and competition from newer nonsteroidal treatments that can support chronic management.
What are the commercial fundamentals for Bryhali?
Bausch Health does not generally disclose Bryhali revenue as a separate public reporting line. Investors therefore must evaluate the product through the Ortho Dermatologics segment, prescription trends, formulary position, gross-to-net deductions and management commentary rather than a transparent product-level income statement.[4]
Revenue drivers
Bryhali revenue depends on:
- Total prescriptions and refill persistence.
- Net price after rebates, discounts and patient assistance.
- Coverage under commercial and government plans.
- Dermatology sales-force productivity.
- Conversion from generic halobetasol and other topical steroids.
- Use in patients seeking a lotion instead of an ointment or cream.
- Expansion within existing dermatology accounts.
Cost structure
The product's manufacturing economics should be favorable relative to biologics and specialty injectables. It is a topical semisolid with no cold-chain requirement and no complex biologic manufacturing process. Costs still include:
- Active pharmaceutical ingredient procurement.
- Vehicle and packaging components.
- Tube or pump filling.
- Quality testing and batch release.
- Sales and marketing.
- Patient support and copay programs.
- Trade and wholesaler discounts.
The main margin risk is commercial rather than manufacturing. A branded topical product may require significant rebates to obtain formulary access, particularly where payers view generic halobetasol as an adequate substitute.
What licensing deals affect Bryhali?
Bryhali was developed and commercialized through the dermatology operations now associated with Bausch Health's Ortho Dermatologics business. Public analysis should distinguish between product ownership, development rights, manufacturing rights and commercial rights because a licensing arrangement may allocate economics among those categories.
No standalone Bryhali royalty stream or major external licensing transaction should be assumed in a valuation unless it is documented in a company filing, transaction announcement or agreement. The absence of separately reported product revenue also limits the ability to calculate an asset-specific royalty burden from public financial statements.[4]
What patent litigation and settlement agreements affect Bryhali?
The relevant litigation questions are whether an ANDA applicant has filed a Paragraph IV certification, whether Bausch Health has sued within the statutory period, whether a 30-month stay applies, and whether the parties have entered a settlement that sets an authorized launch date.
For valuation purposes, a settlement can be more important than the nominal patent expiration date. Key settlement terms include:
- First generic entry date.
- Number of permitted generic entrants.
- Authorized-generic rights.
- Supply obligations.
- Royalty or profit-sharing terms.
- Covenants not to sue.
- Acceleration provisions after patent invalidation.
A litigation-free public record does not establish that a product has no generic risk. Generic applicants may use alternative certification pathways or pursue formulation designs that do not trigger a conventional Paragraph IV dispute.
What manufacturing and intellectual-property barriers protect Bryhali?
The principal manufacturing barrier is topical product equivalence. A competing manufacturer must produce a stable lotion with appropriate rheology, content uniformity, preservative performance, packaging compatibility and release characteristics.
The principal IP barrier is the formulation. If patent claims cover specific excipient combinations, particle characteristics, solvent systems or delivery properties, a generic company may need a non-infringing formulation that remains pharmaceutically equivalent.
These barriers are meaningful but narrower than those protecting complex injectables, inhaled products or biologics. The product does not have the same manufacturing moat as a monoclonal antibody or a device-integrated drug.
What is the investment scenario for Bryhali?
Base case
Bryhali remains a steady branded dermatology product with gradual prescription erosion. Bausch Health maintains distribution and payer coverage, while generic competition remains limited or delayed. Cash generation is positive, but growth is modest because the active ingredient is mature and the indication is narrow.
Bull case
The lotion vehicle produces durable patient and prescriber preference, branded dermatology execution improves, and patent protection delays direct generic competition. Growth could also benefit from better payer coverage or stronger positioning against ointment and foam products.
Bear case
A generic or authorized generic enters earlier than expected, payer rebates increase, and prescribers switch patients to cheaper halobetasol products. Nonsteroidal competitors capture chronic-use patients, reducing both volume and pricing power.
| Variable |
Bull case |
Base case |
Bear case |
| Prescription trend |
Stable to growing |
Gradual decline |
Rapid decline |
| Net price |
Stable |
Moderate rebate pressure |
Heavy discounting |
| Generic timing |
Delayed |
Unclear or later entry |
Early entry |
| Formulation differentiation |
Strong |
Moderate |
Weak |
| Payer access |
Improves |
Maintained |
Deteriorates |
| Strategic value |
Platform dermatology asset |
Cash-generating niche brand |
Harvest or divestiture candidate |
How should investors value Bryhali?
Bryhali should be valued as a branded mature-care product, not as a pipeline biotechnology asset. A practical valuation framework is:
- Forecast prescription volume by payer segment.
- Estimate gross-to-net deductions.
- Model branded erosion under multiple generic-entry dates.
- Apply manufacturing and promotional costs.
- Deduct litigation, regulatory and business-development costs.
- Assign a probability to each patent and entry scenario.
- Discount the resulting cash flows using a risk rate appropriate for a mature branded pharmaceutical.
The most sensitive assumptions are the first generic entry date, annual prescription erosion, net selling price and sales-force allocation. A five-year delay in generic entry can materially increase value, while a rapid post-entry decline can eliminate much of the terminal commercial value.
What should investors monitor?
The highest-value indicators are:
- FDA Orange Book additions or deletions.
- ANDA approvals for halobetasol lotion products.
- Paragraph IV litigation filings.
- Federal court claim-construction or validity decisions.
- Bausch Health disclosures on Ortho Dermatologics sales.
- Prescription and formulary data.
- Changes in copay support.
- New topical psoriasis launches from Dermavant, Arcutis, Amgen, LEO Pharma and generic manufacturers.
- Manufacturing or supply interruptions.
- Any licensing, divestiture or portfolio transaction involving Ortho Dermatologics.
Key Takeaways
- Bryhali is halobetasol propionate lotion, 0.01%, approved for adult plaque psoriasis.
- Its differentiation comes from the lotion vehicle, not a novel active ingredient.
- The product has lower clinical and manufacturing risk than a new molecular entity.
- Generic risk is the central investment issue because halobetasol propionate is an established corticosteroid.
- Formulation patents and topical equivalence requirements may delay entry but do not create a biologic-level moat.
- Bausch Health does not publicly provide a fully transparent standalone Bryhali revenue profile.
- The strongest valuation drivers are generic timing, payer access, branded prescription retention and net pricing.
- Bryhali is best analyzed as a mature branded dermatology cash-flow asset with asymmetric downside from generic entry.
FAQs
Is Bryhali a biologic or a small-molecule drug?
Bryhali is a conventional topical small-molecule drug containing halobetasol propionate. Biosimilar competition does not apply.
Can generic halobetasol automatically substitute for Bryhali?
Not necessarily. Substitution depends on the specific FDA-rated equivalence of the generic product, dosage form, state pharmacy law and payer policy. Generic halobetasol in an ointment or cream is not automatically equivalent to every lotion formulation.
Is Bryhali stronger than over-the-counter hydrocortisone?
Yes. Halobetasol propionate is a very-high-potency topical corticosteroid and is materially more potent than over-the-counter hydrocortisone products. It is prescription-only and carries stronger duration and safety restrictions.
Does Bryhali compete with Zoryve and Vtama?
Yes. Zoryve and Vtama are branded nonsteroidal topical psoriasis therapies. They compete most directly for patients who need chronic treatment or want to avoid topical corticosteroids.
What event would most quickly reduce Bryhali's value?
An FDA-approved generic with broad pharmacy distribution and favorable payer coverage would create the fastest likely decline in Bryhali's branded revenue. A formulation design-around could have a similar effect if it avoids listed patents and achieves commercial acceptance.
References
- U.S. Food and Drug Administration. (2018). Bryhali (halobetasol propionate) lotion, 0.01% prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications.
- Bausch Health Companies Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
